Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review
Journal of Comparative Effectiveness Research · 2025
DOI: 10.57264/cer-2025-0031 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Antonio J García Ruiz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Pediatrics, School of Medicine, University of Malaga, Biomedical Research Institute of Malaga (IBIMA-Bionand), Malaga, S…. Hauptthemen laut MEDLINE: Parkinson Disease, Benzylamines, Alanine, Indans. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
This systematic review aimed to evaluate the comparative efficacy, safety and cost-effectiveness of safinamide (50/100 mg) versus rasagiline (1 mg) in managing Parkinson’s disease (PD). Materials & methods: Randomized clinical trials were identified through systematic searches of PubMed, Embase and Cochrane databases (last searched September 2023). Eligibility criteria included studies assessing Unified Parkinson’s Disease Rating Scale (UPDRS) scores, On/Off time and adverse events. Risk of bias was evaluated using funnel plots, and data synthesis employed odds ratios, number needed to treat (NNT) and incremental cost-effectiveness ratios, calculated using the current costs of safinamide and rasagiline in Spain.
Results
Thirteen trials (n = 4157 participants) were included. Safinamide demonstrated greater efficacy (NNT-UPDRS: 6 vs 8) and safety (number needed to harm-serious adverse events: 135 vs 83) compared with rasagiline. The benefit-risk balance of safinamide was superior, as evidenced by higher likelihood of being helped over harmed ratios. Cost-effectiveness analysis revealed lower costs per NNT for On/Off time with safinamide. While rasagiline treated more patients within a fixed budget, safinamide achieved better responder-to-nonresponder ratios.
Conclusion
Safinamide showed superior efficacy, safety and cost-efficiency compared with rasagiline, supporting its use as a preferred adjunct therapy for PD. Limitations include reliance on clinical trial data and Spanish cost models. Future research incorporating real-world evidence is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Pediatrics, School of Medicine, University of Malaga, Biomedical Research Institute of Malaga (IBIMA-Bionand), Malaga, Spain.
- Department of Neurology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
ORCID-Profile: Antonio J García Ruiz, Nuria García-Agua Soler
Zitieren
APA
García Ruiz, A. J., García, E. M., Gómez Heredia, M. J., Errazquin, F. P., & Soler, N. G. (2025). Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0031
Vancouver
García Ruiz AJ, García EM, Gómez Heredia MJ, Errazquin FP, Soler NG. Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2025-0031
BibTeX
@article{GarcaRuiz2025,
author = {García Ruiz, Antonio J and García, Ester Morales and Gómez Heredia, María José and Errazquin, Francisco Pérez and Soler, Nuria García-Agua},
title = {Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
doi = {10.57264/cer-2025-0031}
}
EUVIMED